In8Bio (INAB) Common Equity (2020 - 2026)
In8Bio's Common Equity was $18.36 million in Q2 2026, up 20.5% from $15.24 million a year earlier but down 19.4% from the prior quarter.
Powered by 
Analysis
In8Bio (INAB) Common Equity (2020 - 2026) Analysis & Trends
At the end of FY2025, Common Equity at In8Bio came in at $27.56 million, up 90.3% from FY2024.
- In earlier years, Common Equity was $14.48 million in FY2024 (-41.9%), $24.94 million in FY2023 (+9.7%), $22.73 million in FY2022 and -$38.18 million in FY2021.
- Quarterly Common Equity has moved between -$38.18 million (Q4 2021) and $43.04 million (Q3 2021) over five years.
- Compared with a year earlier, Common Equity has increased for five straight quarters, with growth averaging 15.8% over the last eight quarters.
- The best year-over-year quarter for Common Equity over five years was Q4 2025 (growth of 90.3%); the worst was Q3 2024 (a decline of 51.6%).
- Per Business Quant data, INAB's Common Equity in the three quarters before Q2 2026 was $22.78 million (Q1 2026), $27.56 million (Q4 2025) and $13.19 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,137.66 Bn | 1,106.24 Bn | 19.71 Bn | 33.88 Bn |
| 2 | Johnson & Johnson | 636.13 Bn | 556.00 Bn | 17.30 Bn | 81.53 Bn |
| 3 | AbbVie | 505.28 Bn | 478.39 Bn | 12.70 Bn | -5.94 Bn |
| 4 | Merck | 358.10 Bn | 312.48 Bn | 12.21 Bn | 41.98 Bn |
| 5 | Novartis Ag | 292.59 Bn | 256.58 Bn | 11.24 Bn | 41.95 Bn |
| 6 | Astrazeneca | 265.81 Bn | 239.50 Bn | 12.86 Bn | 50.37 Bn |
| 7 | Amgen | 237.53 Bn | 192.93 Bn | 7.24 Bn | 11.69 Bn |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn | 11.83 Bn |
| 9 | Pfizer | 171.17 Bn | 117.82 Bn | 10.94 Bn | 85.49 Bn |
| 10 | In8Bio | 20.25 Mn | -58.10 Mn | - | 18.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.36 Mn |
| Mar 31, 2026 | 22.78 Mn |
| Dec 31, 2025 | 27.56 Mn |
| Sep 30, 2025 | 13.19 Mn |
| Jun 30, 2025 | 15.24 Mn |
| Mar 31, 2025 | 13.88 Mn |
| Dec 31, 2024 | 14.48 Mn |
| Sep 30, 2024 | 8.59 Mn |
| Jun 30, 2024 | 13.62 Mn |
| Mar 31, 2024 | 17.53 Mn |
| Dec 31, 2023 | 24.94 Mn |
| Sep 30, 2023 | 17.76 Mn |
| Jun 30, 2023 | 21.80 Mn |
| Mar 31, 2023 | 16.79 Mn |
| Dec 31, 2022 | 22.73 Mn |
| Sep 30, 2022 | 29.56 Mn |
| Jun 30, 2022 | 26.57 Mn |
| Mar 31, 2022 | 32.84 Mn |
| Dec 31, 2021 | -38.18 Mn |
| Sep 30, 2021 | 43.04 Mn |
API Access
In8Bio Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=INAB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "INAB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=INAB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();